Connect with us

Stock Market Breaking News

ParcelPal (PTNYF) (PKG) Welcomes Brian Storseth to the Board of Directors and Acting Chairman

Daniel Chase

Published

on

VANCOUVER , British Columbia, Feb. 27, 2019 /PRNewswire/ — ParcelPal Technology Inc. (“ParcelPal” or the “Company”), (CSE:PKG) (PKG.CN) (PT0.BE) (PTNYF) is pleased to welcome Brian Storseth as Chairman of the Board of Directors.

Mr. Storseth is a businessman and was a Member of Parliament (MP) for the electoral district of Westlock-St Paul for the Conservative Party of Canada for 9 years from 2006-2015. During his tenure as an MP he served on committees for Aboriginal Affairs, Agriculture and Agri-food Canada.

Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market

Brian currently serves as Chairman of Reliq Health Technologies’ (RHT.V) or (RQHTF) Board of directors and a managing partner of Maverick Capital Fund. In addition to his current business affairs, Brian has also taken an active role to give back to his community. He is the founder of the Westlock Women’s Hope Resource Centre and currently is on the Board of Progress Mental Health. Brian studied political science at the University of Alberta while simultaneously working in Office of the Speaker of the Legislative Assembly of Alberta.

President and CEO, Kelly Abbott states, “Brian is an incredibly accomplished business leader and policy expert, having spent 9 years in Ottawa in the House of Commons. He is intimately familiar with ParcelPal’s business, our plans for future expansion and will be an invaluable asset moving forward as we navigate multiple opportunities across various Government entities, namely within the Ontario market. We are excited to leverage his network, experience and leadership to assist with our national expansion plans.”

Brain Storseth stated, “I am thrilled to join ParcelPal’s board as a Chairman. Having watched the progress of ParcelPal over the past year, I am very impressed with management as they begin their rollout across Canada. I am looking forward to providing guidance and value across the business in all verticals.”

About ParcelPal Technology Inc.

ParcelPal is a technology-driven logistics company that connects consumers to the goods they love. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour. The Company offers on-demand delivery of merchandise from leading retailers, restaurants, medical marijuana dispensaries and liquor stores in Vancouver and soon in major cities Canada-wide.

ParcelPal Website: www.parcelpal.com

The Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.

CSE – Symbol: PKG

FSE – Symbol: PT0

OTC – Symbol: PTNYF

Forward Looking Information

This news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal.  Forward looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects”, “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. 

The Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement.  The forward looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.

An Affiliate of JSG Communications, MIDAM VENTURES LLC has been compensated $75,000 per month for 3 months by ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG). We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.

Please click here for full disclaimer.

Continue Reading
Click to comment

Biotechnology

PharmaCyte Biotech (PMCB) and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes

Joe Samuel

Published

on

biotech stocks to watch

PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes with the potential to express higher levels of insulin.

[FULL REPORT] The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are pleased to have come to an agreement with UTS that allows us to take the Melligen cells to the next level in our development of a ‘bioartificial pancreas’ for the treatment of Type 1 and insulin-dependent Type 2 diabetes. If we are successful, it will bring to fruition the many years of research that have been conducted by Professor Ann Simpson and her colleagues at UTS as well as PharmaCyte in developing these remarkable insulin-producing cells.”

Melligen cells are human liver cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body. PharmaCyte has obtained the exclusive worldwide license rights from UTS to use these cells to develop a therapy for Type 1 and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Box® technology to protect the Melligen cells from immune system attack in the body and thus function as a “bioartificial pancreas” for purposes of insulin production.

The work undertaken by PharmaCyte, UTS and PharmaCyte’s International Diabetes Consortium over the last two years has resulted in an opportunity to re-engineer the Melligen cells with the aim of increasing their insulin production as well as the bioactivity of the produced insulin. With this new agreement in place, the research will be done in Australia under the leadership of Prof. Ann Simpson, the developer of the original Melligen cell line.

The unique properties that set the Melligen cells apart from all other available insulin-producing cell types, include their robustness, their ability to withstand an attack from cell-toxic molecules that typically lead to the destruction of insulin-producing cells and their suitability for cost-efficient pharmacological-grade large scale production. In contrast to primary beta islet cells of the pancreas, which normally produce insulin and stem-cell-derived insulin producing cells, Melligen cells are a scalable and a highly characterized cell line that can readily be expanded in a bioreactor to generate the amounts of cells needed for cell banking, testing and production.

Professor Simpson commented, “We are extremely pleased that we have come to an agreement with PharmaCyte to continue our work on the Melligen cells and advance them to their full potential. Both UTS and PharmaCyte are investing in this important research because we believe in the significant health impact potential. This takes us a step closer to eliminating the need for diabetics to inject insulin daily and, more importantly, protects them from developing the debilitating complications of the disease such as blindness, neuropathy and possible amputations, kidney failure and cardiovascular problems. We look forward to working with PharmaCyte and its International Diabetes Consortium to improve the Melligen cells and to utilize them with the Cell-in-a-Box®encapsulation technology to create a potential cure for diabetes.”

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

International Diabetes Consortium

PharmaCyte Biotech has established an International Diabetes Consortium (Diabetes Consortium) that consists of world-renowned physicians and scientists from several countries, all of whom share the same goal of developing a treatment for Type 1 and insulin-dependent Type 2 diabetes.

In addition to the Chief Executive Officer, Chief Operating Officer, Chief Scientific Officer and Chief Medical Officer of PharmaCyte, the Diabetes Consortium is made up of well-known physicians and scientists from leading Universities in Munich, Germany, Mannheim, Germany, Vienna, Austria, Barcelona, Spain, Copenhagen, Denmark, and Sydney, Australia. It also involves members from the Karolinska Institute in Stockholm, Sweden, the Vorarlberg Institute for Vascular Investigation and Treatment in Feldkirch, Austria and the biotech company Austrianova in Singapore.

Dr. Eva Maria Brandtner leads the Consortium and is PharmaCyte’s Director of Diabetes Program Development. Dr. Brandtner, who is a consultant for PharmaCyte, previously served as the Chief Scientist with Austrianova. In that role, she conducted preclinical studies with the Melligen cells. Prof. Ann. M Simpson and her colleagues at the University of Technology Sydney developed the Melligen cells. Prof. Simpson is a member of the Consortium.

In addition to key personnel from PharmaCyte, Dr. Brandtner and Prof. Simpson, the Diabetes Consortium includes Prof. Dr. Walter H. Günzburg, the Chief Scientific Officer of PharmaCyte Biotech and the Chief Technical Officer of Austrianova, and Dr. Brian Salmons, the Chief Executive Officer of Austrianova and a member of PharmaCyte’s Medical and Scientific Advisory Board. It also includes research scientists Prof. Dr. Eckhard Wolf and Prof. Dr. Rüdiger Wanke from the Ludwig-Maximillian University (LMU) in Munich, Germany. Both, together with their colleagues at LMU, have developed unique animal models for insulin-dependent diabetes. Other key members of the Diabetes Consortium include Prof. Dr. Hans-Peter Hammes, Professor of Internal Medicine and Endocrinology, Faculty of Clinical Medicine Mannheim of Heidelberg University and Section Leader for Endocrinology and Diabetology, Mannheim, Germany, Prof. Dr. Thomas Stratman of the University of Barcelona in Spain and Prof. Dr. Axel Kornerup Hanson of the University of Copenhagen in Denmark.

About University of Technology Sydney

UTS is a dynamic and innovative university in central Sydney. One of Australia’s leading universities of technology, UTS has a distinct model of learning, strong research performance and a leading reputation for engagement with industry and the professions. Based in the vibrant creative and start-up precinct in Ultimo, it has more than 40,000 students and is rated No.1 ‘young’ university in Australia in both the QS and Times Higher Education rankings.

More information about UTS can be found at www.uts.edu .au.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the United States Securities and Exchange Commission.

More information about PharmaCyte can be found at www.PharmaCyte .com. It can also be obtained by contacting Investor Relations.

Contact:Dr. Gerald W. Crabtree 
Investor Relations: 
PharmaCyte Biotech, Inc. 
Investor Relations Department 
Telephone: 917.595.2856 
Email: Info@PharmaCyte. com

Continue Reading

Cannabis

Driven Deliveries, Inc. (DRVD) Announces Christian Schenk as New Chief Executive Officer

Jon Phillip

Published

on

marijuana stock

SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) — Driven Deliveries, Inc., (DRVD), the American’s first and only publicly traded cannabis delivery company, announced today that Mr. Christian Schenk has been named its new Chief Executive Officer, effective on May 3, 2019. Mr. Schenk succeeds Chris Boudreau, who served as CEO since Driven’s inception.  Mr. Boudreau will remain in an advisory role with the company.

Mr. Schenk is a Canadian born entrepreneur and investor with a proven track record of success within the transportation technology sector. He has previously developed and sold two telematics companies; Telkar based in Canada and Elcon based in Europe. In 2010 Schenk joined XATA following the acquisition of Turnpike Global and Geologic. Mr. Schenk was tasked with merging three distinct businesses into a single entity and solution which once complete lead to the rebranding of the company to XRS (NASDAQ; XRSC).   XRS was sold to Omnitracs in 2014 for $178M. Schenk recognized the opportunity to shift many of the IoT (Internet of things) learnings such as data analytics, machine learning and predictive modeling to the Social and Content Marketing sector.

“Management is looking forward to leveraging Mr. Schenk’s extensive knowledge of transportation technology and his extensive industry relationships,” said Mr. Brian Hayek, Co-founder and President of Driven Deliveries, Inc.  “The addition of Christian is another example of Driven’s commitment to establishing a strong portfolio of human capital, capable of building and maintaining long-term growth platform. 

Mr. Hayek continued, “Management would also like to thank Chris Boudreau for his service to the company.  Chris was instrumental in assisting Driven through the go-public process and securing our initial cannabis delivery licenses.  We wish him well in his future endeavors.”

In 2017 Schenk entered the payments industry where he formed several new ventures including a freight factoring alternative, BNK which pays truck drivers based on achieving route defined milestones and IPTS a recreation & hospitality employee same day pay solution that enables employees to get paid daily vs waiting till payday.  Schenk holds several board seats in the rideshare, supply chain and mobile technology industries. Previously, he formed one of the largest networks of professional truck drivers, ONE20 which was sold in mid 2017.  ONE20 offered routing, navigation and social intelligence to its more than 700,000 members and monetized by selling content and advertising based on personal personas, relevance and location.

“Driven is in such an incredible position to dominate the cannabis delivery and distribution markets,” said Christian Schenk. “Looking at the current valuations and capital placement in the freight and ride share categories it is my intention to leverage past learnings and partnerships to further separate Driven from its single threaded competitors. We will focus on solid sustainable business ventures while keeping an eye on healthy growth both inside our core markets and expanding into new states and potentially north of the border.  We know where the brands need our help and we know how to build loyal customers.  The cross section of those strengths will be where we deliver the most value to the industry and our shareholders” 

Forward-looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

About Driven

Driven Deliveries, Inc. first and only publicly traded cannabis delivery service operating within the United States and listed on American Exchanges.  Founded by experienced technology and cannabis executives, the Company provides on-demand marijuana delivery, in select cities where allowed by law.  Driven provides the legal cannabis consumers the ability to purchase and receive their marijuana in a fast and convenient manner.  By 2020, legal cannabis revenue in the U.S. market is projected to hit $23 billion.  In leveraging consumer trends, and offering a proprietary, turnkey delivery system to its customers, management believes it is uniquely positioned to best serve the needs of the emerging cannabis industry and capture notable market share within the sector. For more information, please visit https://GoDriven. com/ and review Driven’s filings with the U.S. Securities and Exchange Commission.

Continue Reading

Cannabis

Driven Deliveries Inc. (DRVD) Completes Acquisition of Ganjarunner, Inc. First-Year Revenue Expected to Exceed $4 Million

Joe Samuel

Published

on

cannabis market

The transaction significantly bolsters Driven’s Brand-to-Consumer delivery and will expand the Ganjarunner brand throughout California

SAN DIEGO, June 25, 2019 (GLOBE NEWSWIRE) — Driven Deliveries, Inc., (DRVD), the world’s first publicly traded cannabis delivery company, announced today that the company has completed the acquisition of Ganjarunner, Inc., a cannabis delivery company that provides high-quality lab-tested, pesticide-free medicinal and recreational products throughout California.

In addition to growing Ganjarunner’s customer base, the acquisition of Ganjarunner will allow for Driven to leverage its brand-to-consumer model across virtually the entire state of California. The subsidiary will provide Driven with multiple fulfillment centers, an additional delivery license in California, and a unique technology platform that will allow for improved efficiency. Ganjarunner has shown continuous revenue growth since its inception. During the previous 12 months, the Ganjarunner, Inc. successfully completed 18,854 deliveries to more than 7,748 customers and has experienced year over year revenue growth of 49.3%. As an subsidiary of Driven, Ganjarunner is projected to reach to $4.1 million in revenue by the end of 2019.  

“The acquisition and integration of Ganjarunner is a vital step in establishing ourselves as a market leader within the rapidly expanding California cannabis marketplace,” said, Mr. Christian Schenk. “This acquisition provides us meaningful topline growth and establishes a platform capable of supporting significant expansion.  We believe we are well-positioned to establish ourselves as a market leader within the $5 billion California cannabis market.  Driven has already identified similarly accretive targets which we believe would further expand our operating footprint.  We expect 2019 to continue to serve as an exciting time for Driven as we remain focused on increasing revenue, expanding margins and enhancing overall shareholder value.”

“We are pleased to officially announce Ganjarunner, Inc. and Driven will operate as one,” stated, Mr. Chris Haas, CEO of Ganjarunner.  “The Ganjarunner management team is staying with the combined company as we are believers in the growth of Driven and Ganjarunner.   Our integration is fully underway with a key focus on our logistics and IT infrastructure. This merger enables us to expand into new delivery markets while remaining a leader in the customer-centric, cannabis delivery industry.”

Forward-looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

About Driven

Driven Deliveries, Inc. is the only publicly traded cannabis delivery service operating within the United States.  Founded by experienced technology and cannabis executives, the Company provides on-demand marijuana delivery, in select cities where allowed by law.  Driven provides the legal cannabis consumers the ability to purchase and receive their marijuana in a fast and convenient manner.  By 2020, legal cannabis revenue in the U.S. market is projected to hit $23 billion.  In leveraging consumer trends, and offering a proprietary, turnkey delivery system to its customers, management believes it is uniquely positioned to best serve the needs of the emerging cannabis industry and capture notable market share within the sector. For more information, please visit https://GoDriven .com/ and review Driven’s filings with the U.S. Securities and Exchange Commission.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com